Product image of Mulpleo (Lusutrombopag) supplied by GNH India

Mulpleo

Active Ingredient:
Lusutrombopag
Origin:
EU

Mulpleo (Lusutrombopag)

Lusutrombopag, the active ingredient in Mulpleo, is a thrombopoietin receptor agonist presented as an oral tablet for oral administration. It is indicated for the management of thrombocytopenia in liver disease patients who are scheduled for invasive procedures, helping to raise platelet counts prior to surgery.

GNH India supplies Mulpleo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide, providing reliable sourcing for regulated markets and supporting clinical needs across Europe and other regions.

Manufacturer / TM Owner

Shionogi B.V.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Lusutrombopag is a thrombopoietin receptor agonist used to treat conditions related to low platelet counts.

  • Thrombocytopenia in chronic liver disease undergoing invasive procedures: Increases platelet count to reduce bleeding risk before surgery.

How It Works

  • Lusutrombopag binds to the thrombopoietin (TPO) receptor c‑Mpl on megakaryocyte precursors, activating intracellular signaling pathways that promote megakaryocyte proliferation and differentiation, thereby enhancing platelet production in the bone marrow.

Side Effects

Lusutrombopag may cause a range of adverse reactions, which are categorized by frequency.

Common Side Effects

  • Headache: mild to moderate head pain reported during therapy.
  • Nausea: occasional feeling of stomach upset.
  • Fatigue: general tiredness experienced by some patients.
  • Diarrhea: loose stools occurring in a minority of users.
  • Abdominal pain: discomfort in the stomach area.
  • Dizziness: transient light‑headedness.

Serious or Rare Side Effects

  • Thrombosis: formation of abnormal blood clots, potentially life‑threatening.
  • Severe hepatic dysfunction: marked liver enzyme elevations or failure.
  • Anaphylaxis: rare severe allergic reaction requiring immediate medical attention.
  • Myocardial infarction: rare heart attack events.
  • Portal vein thrombosis: clot formation in the portal vein.
  • Severe bleeding: unexpected hemorrhage despite platelet increase.

Precautions & Warnings

When prescribing Lusutrombopag, clinicians should consider several safety precautions.

  • Dose adjustment: Use caution in patients with severe hepatic impairment.
  • Bleeding risk: Monitor platelet counts before and after treatment to assess efficacy and safety.
  • Thrombotic risk: Assess for personal or family history of thrombosis prior to initiation.
  • Pregnancy: Use only if the potential benefit justifies the potential risk; data are limited.
  • Drug interactions: Review concomitant medications that affect platelet function or metabolism.
  • Store at ambient temperature below 25°C: keep in the original pack, protect from moisture.

Avoid Interactions

Lusutrombopag can interact with other medicines, requiring attention to potential effects on efficacy and safety.

Major Interactions (Avoid)

  • Concurrent use with other thrombopoietin receptor agonists: may increase risk of excessive platelet rise.
  • Strong CYP3A4 inducers (e.g., rifampin): may reduce lusutrombopag exposure and effectiveness.
  • Anticoagulants (e.g., warfarin): may alter bleeding risk and require close monitoring.

Moderate Interactions (Monitor Closely)

  • Antiplatelet agents (e.g., aspirin): monitor for additive bleeding risk.
  • Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase gastrointestinal bleeding potential.
  • Herbal supplements affecting platelet function (e.g., ginkgo biloba): monitor platelet response.

Frequently Asked Questions

Mulpleo contains the active ingredient lusutrombopag and is prescribed to increase platelet counts in patients with chronic liver disease who need to undergo invasive medical or surgical procedures. By raising platelet levels, it helps reduce the risk of bleeding during these interventions.

Lusutrombopag acts as an agonist of the thrombopoietin (TPO) receptor, known as c‑Mpl, on bone‑marrow megakaryocyte precursors. Activation of this receptor triggers signaling pathways that stimulate megakaryocyte proliferation and maturation, leading to increased production of platelets.

The dosage of Mulpleo is individualized by the treating physician based on the patient’s platelet count, liver function, and the planned procedure. The prescriber determines the appropriate strength, frequency, and duration of therapy in accordance with clinical guidelines.

Safety data for lusutrombopag in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Mulpleo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to lusutrombopag is avatrombopag, another oral thrombopoietin receptor agonist. Both agents increase platelet counts, but they differ in dosing schedules, metabolic pathways, and specific regulatory approvals. Clinicians choose based on patient characteristics, drug‑interaction profile, and local prescribing guidelines.

Mulpleo tablets should be stored at ambient temperature below 25 °C, in the original packaging, and protected from moisture and direct sunlight. Keep the product out of reach of children and do not use if the packaging is damaged or the tablets appear discolored.

Mulpleo is taken orally as a tablet with a glass of water. It is usually administered on a specific day before the planned invasive procedure, as directed by the prescribing physician, and should be swallowed whole without crushing or chewing.

Serious risks include the development of thrombosis (including portal vein thrombosis), severe hepatic dysfunction, and rare cases of anaphylaxis or myocardial infarction. Patients should be monitored closely for signs of abnormal clot formation or liver injury during treatment.

Mulpleo is contraindicated in patients with known hypersensitivity to lusutrombopag or any tablet excipients, those with active uncontrolled thrombotic disorders, and individuals with severe hepatic impairment where the drug’s safety has not been established. A thorough medical history should be reviewed before initiation.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Lusutrombopag

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT